Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acurx Pharmaceuticals, Inc. - Common Stock (NQ:ACXP)

0.3300 -0.0290 (-8.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acurx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are a major topic this morning as we check out the biggest ones worth keeping an eye on for Tuesday! 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Preview: Acurx Pharmaceuticals's Earnings
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday, 56 stocks hit new 52-week lows. 
Via Benzinga
Recap: Acurx Pharmaceuticals Q1 Earnings
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday saw 59 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 50 companies reached new 52-week lows. 
Via Benzinga
A Preview Of Acurx Pharmaceuticals's Earnings
Via Benzinga
Acurx Pharmaceuticals's Earnings: A Preview
Via Benzinga
Earnings Scheduled For May 12, 2023
Companies Reporting Before The Bell • Honda Motor Co (NYSE:HMC) is expected to report earnings for its fourth quarter. 
Via Benzinga
In The Queue: AcurX Pharmaceuticals Earnings…Here’s What Investors Need To Know Before Thursday ($ACXP)
Via AB Newswire
Exposures Product Safety
Race To The Cure: Here’s Why Acurx Pharmaceuticals Could Win The Battle To Treat C. difficile ($ACXP)
Via AB Newswire
Acurx Pharmaceuticals CEO Is Confident His Ibezapolstat Can Earn Front-Line Designation To Treat C. difficile…Here’s Why ($ACXP)
Via AB Newswire
Acurx Is Vying for Standard of Care in Treating Primary and Recurrent C. diff
C. diff is a life-threatening bacterial infection that causes diarrhea and colitis, which is the inflammation of the colon. Approximately 600,000 are diagnosed with C. diff each year in the United... 
Via TheNewswire.com
Topics Death
Exposures Death Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022
Via Benzinga
Acurx Pharmaceuticals Surges 29% In August, Here’s Why The ACXP Bulls Expect Much More To Come ($ACXP)
Via AB Newswire
91 Biggest Movers From Friday
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers bluebird bio (NASDAQ:BLUE) shares rose 53.4% to $6.12 during Friday's after-market session. Trading volume for this security closed at 5.0 million, accounting for 206.3% of its average full-day... 
Via Benzinga
Pfizer’s CDI Trial Miss Puts Acurx Pharmaceuticals Ibezapolstat In Front-Line Position, Here’s Why Big Pharma May Come Calling ($ACXP)
Via AB Newswire
Exposures Product Safety
Acurx Pharmaceuticals Is Under The Radar, That’s Excellent News For Investors Wanting Exposure To Billion Dollar CDI Treatment Market ($ACXP)
Via AB Newswire
Exposures Product Safety
Acurx Pharmaceuticals Stands As Front-Line CDI Treatment Contender After Pfizer Misses Primary Endpoint In CDI Drug Trial (NASDAQ: ACXP)
Via AB Newswire
Exposures Product Safety
90 Biggest Movers From Yesterday
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) surged 70.5% to close at $0.1330 on Thursday after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered... 
Via Benzinga
Earnings Scheduled For March 17, 2022
Companies Reporting Before The Bell • TransGlobe Energy (NASDAQ:TGA) is estimated to report earnings for its fourth quarter. • Ikena Oncology (NASDAQ:IKNA) is... 
Via Benzinga
Acurx Pharmaceuticals Ibezapolstat Targets Front-Line Opportunity After Pfizer Fails To Reach CDI Trial Primary Endpoint (NASDAQ: ACXP)
Via AB Newswire
Acurx Pharmaceuticals’ Phase 2b Antibiotic Candidate To Treat C. Difficile Shows 100% Cure And 100% Sustained Cure In Potentially Transformative Study (NASDAQ: ACXP)
Via AB Newswire
53 Biggest Movers From Friday
Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares climbed 100% to close at $3.80 on Friday after gaining around 9% on Thursday. Dave Inc. (NASDAQ: DAVE) jumped 30.3% to settle... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Biophytis (NASDAQ:BPTS) shares rose 12.3% to $5.28 during Friday's regular session. The market value of their outstanding shares is at $68.0 million. Intra-... 
Via Benzinga
Acurx Pharmaceuticals’ Ibezapolstat Takes Center Stage After Summit Therapeutics Misses Phase 3 C.Diff Trial Endpoints (NASDAQ: ACXP)
Via AB Newswire
If A Santa Claus Rally Comes To Town, Expect Acurx Pharmaceuticals To Be On The Lead Sleigh…Here’s Why (NASDAQ: ACXP)
Via AB Newswire
With A Phase 2b Trial In Progress, Acurx Pharmaceuticals May be The Most Undervalued Biotech On The Market…Here’s Why (NASDAQ: ACXP)
Via AB Newswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.